Entero Therapeutics Overview
Entero Therapeutics (ENTO) has a ROE of -53.47%, below the sector sector average of -5.68%.
Get informed when a big investor buys or sells
+ Follow-53.47%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Entero Therapeutics (ENTO) currently reports a ROE of -53.47%. That is below the sector sector average of -5.68%. Use the charts on this page to explore Entero Therapeutics's ROE history and peer comparisons.
Entero Therapeutics's ROE of -53.47% is lower than the its sector sector average of -5.68%. That is roughly 840.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Entero Therapeutics's current -53.47% should be judged against industry norms (sector average: -5.68%) and against ENTO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -53.47%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.68%. From there, open related valuation or income-statement pages for Entero Therapeutics, and consider following ENTO for alerts when major investors trade the stock.
